Laura Holman to Adult
                            
                            
                                This is a "connection" page, showing publications Laura Holman has written about Adult.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.612
         
        
        
     
 
    
        
        - 
            Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol. 2020 01; 156(1):100-106.
            
            
                Score: 0.069
             
- 
            Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough. Gynecol Oncol. 2018 04; 149(1):89-92.
            
            
                Score: 0.062
             
- 
            Factors prognostic of survival in advanced-stage uterine serous carcinoma. Gynecol Oncol. 2017 07; 146(1):27-33.
            
            
                Score: 0.058
             
- 
            Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol. 2014 May; 133(2):283-6.
            
            
                Score: 0.046
             
- 
            Germline POT1 Variants in a Pan-Cancer Cohort. JCO Precis Oncol. 2025 Jul; 9:e2400946.
            
            
                Score: 0.025
             
- 
            Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecol Oncol. 2025 Apr; 195:122-133.
            
            
                Score: 0.025
             
- 
            Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278). Gynecol Oncol. 2025 Apr; 195:50-58.
            
            
                Score: 0.025
             
- 
            Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278). Gynecol Oncol. 2025 Apr; 195:59-65.
            
            
                Score: 0.025
             
- 
            Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2025 Feb 15; 131(4):e35757.
            
            
                Score: 0.025
             
- 
            Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial. Nat Commun. 2025 Jan 09; 16(1):553.
            
            
                Score: 0.025
             
- 
            Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment. Sci Rep. 2024 11 16; 14(1):28319.
            
            
                Score: 0.024
             
- 
            Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992.
            
            
                Score: 0.024
             
- 
            Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70?years and over. Gynecol Oncol. 2024 08; 187:221-226.
            
            
                Score: 0.024
             
- 
            Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
            
            
                Score: 0.023
             
- 
            Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis. Gynecol Oncol. 2021 09; 162(3):532-538.
            
            
                Score: 0.019
             
- 
            A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
            
            
                Score: 0.019
             
- 
            Multiple Luteinized Follicle Cysts of the Ovary in a Patient With a Pituitary Adenoma: Report of a Case and Review of the Literature. Int J Gynecol Pathol. 2019 Nov; 38(6):562-567.
            
            
                Score: 0.017
             
- 
            Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. Gynecol Oncol. 2019 09; 154(3):461-466.
            
            
                Score: 0.017
             
- 
            Primary and acquired platinum-resistance among women with high grade serous ovarian cancer. Gynecol Oncol. 2016 08; 142(2):225-30.
            
            
                Score: 0.014
             
- 
            Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015 Dec; 182(3):289-301.
            
            
                Score: 0.013
             
- 
            Laparoscopic supracervical hysterectomy with morcellation: should it stay or should it go? J Minim Invasive Gynecol. 2015 Feb; 22(2):185-92.
            
            
                Score: 0.012
             
- 
            Assessment of palliative care training in gynecologic oncology: a gynecologic oncology fellow research network study. Gynecol Oncol. 2014 Aug; 134(2):379-84.
            
            
                Score: 0.012
             
- 
            A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010 Dec 16; 29(2):304-13.
            
            
                Score: 0.009